Cohort Studies

  • Bryan Kestenbaum

Learning Objectives

  1. 1.
    The fundamentals of a cohort study design are:
    1. a.

      Identify people who are free of disease at the beginning of the study

    2. b.

      Assemble cohorts of exposed and unexposed individuals

    3. c.

      Follow cohorts for the development of incident outcomes

    4. d.

      Compare the risks of incident outcomes in each cohort

  2. 2.
    Cohort studies have certain advantages:
    1. a.

      Can discern temporal relationships between the exposure and the outcome

    2. b.

      Can be used to evaluate multiple outcomes

  3. 3.
    Cohort studies have certain disadvantages:
    1. a.

      Observational design: other factors may be responsible for observed association

    2. b.

      May be inefficient for studying rare diseases or those with long latency periods

  4. 4.

    Cohort studies can be used to evaluate the risks and benefits of medication use.

  5. 5.

    Cohort studies can be used to calculate relative and attributable risks of disease.



Hormone Replacement Therapy Kidney Transplant Peripheral Arterial Disease Attributable Risk Serum Retinol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 8.
    Dooley AC, Weiss NS, Kestenbaum B. Increased risk of hip fracture among men with CKD. Am J Kidney Dis. Jan 2008;51(1):38–44.CrossRefPubMedGoogle Scholar
  2. 16.
    Smith NL, Psaty BM, Heckbert SR, Tracy RP, Cornell ES. The reliability of medication inventory methods compared to serum levels of cardiovascular drugs in the elderly. J Clin Epidemiol. Feb 1999;52(2):143–146.CrossRefPubMedGoogle Scholar
  3. 17.
    Belanger CF, Hennekens CH, Rosner B, Speizer FE. The nurses’ health study. Am J Nurs. Jun 1978;78(6):1039–1040.CrossRefPubMedGoogle Scholar
  4. 18.
    Avorn J. In defense of pharmacoepidemiology – embracing the yin and yang of drug research. N Engl J Med. Nov 29 2007;357(22):2219–2221.CrossRefPubMedGoogle Scholar
  5. 19.
    Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care. Nov 2000;23(11):1605–1611.CrossRefPubMedGoogle Scholar
  6. 20.
    Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. Jun 14 2007;356(24):2457–2471.CrossRefPubMedGoogle Scholar
  7. 21.
    Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. Aug 7 2003;349(6):523–534.CrossRefPubMedGoogle Scholar
  8. 22.
    Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women’s Health Initiative clinical trial. Am J Epidemiol. Sep 1 2005;162(5):404–414.CrossRefPubMedGoogle Scholar
  9. 23.
    Michaelsson K, Lithell H, Vessby B, Melhus H. Serum retinol levels and the risk of fracture. N Engl J Med. Jan 23 2003;348(4):287–294.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.University of WashingtonSeattleUSA

Personalised recommendations